Partnering
SpringWorks Therapeutics is committed to building strong partnerships to develop new medicines for the patients and families that are counting on us. By working together, we can ignite the power of promising science to unleash new possibilities for patients.
Partnering/Business Development
Expanding our pipeline through preclinical and clinical collaborations is a key component of our business model. SpringWorks has created a channel for evaluating additional assets to license from Pfizer and is also actively pursuing new licensing and partnership opportunities with other innovators. We are working to grow our portfolio and to leverage our best-in-class clinical development capabilities to help advance promising science as efficiently as possible.
If you are interested in partnering with SpringWorks, please contact us at partnering@springworkstx.com.
Our Partners
We focus on developing true partnerships, with patients at the center of our ambitions and efforts. Our belief is that by teaming with innovators and advocates across patient groups, academic institutions, and industry, we can collectively create new solutions for the patients who are counting on us.
Patient Groups
The mission of the Desmoid Tumor Research Foundation is to accelerate the development of improved therapies and ultimately find a cure for desmoid tumors. The foundation collaborates with dedicated researchers and clinicians worldwide to improve the lives of patients through education, awareness and support.
The Children’s Tumor Foundation is on a mission to drive research, expand knowledge, and advance care for the neurofibromatosis community. Frustrated by the traditional model of drug research and driven by its belief in a culture of collaboration, the foundation has formulated a strategic plan to accelerate the cure for neurofibromatosis by actively engaging all stakeholders in NF research: patients, scientists, doctors, pharmaceutical companies and the biotechnology field.
Industry Partners
SpringWorks Therapeutics was originally conceived by Pfizer as an innovative way to advance investigational therapies that may hold significant promise for underserved patients. In 2017, we launched with four clinical-stage experimental therapies from Pfizer and continue to partner with the organization to identify potential developmental medicines where we can accelerate development and, ultimately, deliver life-changing therapies to the patients who need them.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
